$APVO

Aptevo Therapeutics (NASDAQ:APVO) said it will induce holders to exercise existing common warrants for cash at a $4.03 exercise price, issuing inducement warrants for up to 1,274,610 shares. Separately, it plans a PIPE selling up to 861,708 shares (or pre-funded warrants) plus common warrants for up to 4,308,540 shares, also at $4.03. Gross proceeds total about $4.5 million, for working capital.

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K 0001671584 false 0001671584 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Aptevo Therapeutics (Nasdaq:APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Aptevo will supply multispecific targeting assets starting with Nectin-4; Niowave will provide radioisotopes and manufacturing, including Actinium-225. At closing, Niowave made an at-the-market equity investment for a 7.9% stake, potentially rising to 19.99% via warrant exercises.

Aptevo Therapeutics (NASDAQ: APVO) detailed its bispecific cancer pipeline and clinical trial data for its lead acute myelogenous leukemia (AML) candidate, mipletamig, in its latest 10-K filing. Mipletamig, a CD123xCD3 T-cell engager, demonstrated an 86% clinical benefit rate and no cytokine release syndrome in frontline AML patients during the RAINIER trial. The company is also advancing ALG.APV-527 for solid tumors, as well as six preclinical candidates leveraging its ADAPTIR and ADAPTIR-FLEX platforms.

Aptevo Therapeutics Inc has reported its earnings results for the quarter ended September 30. The summary, provided by Refinitiv and republished by Reuters on TradingView, is a brief announcement. The full details of the earnings report would require accessing the linked Reuters content.

Aptevo Therapeutics has secured a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP, which, when combined with existing cash, extends the company's funding runway into 2029. This capital infusion will support the advancement of its clinical and preclinical multispecific anti-cancer agents, including mipletamig, which is being evaluated for frontline AML. The ELOC provides financial flexibility and strategic optionality, allowing Aptevo to draw funds incrementally under market-based conditions to achieve key milestones.

This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market session. Six companies were gainers, led by Mobile-health Network, Bio Green Med Solution, and NovaBridge Biosciences, while six were losers, including Halozyme Therapeutics, Xencor, and Quince Therapeutics. The movements include percentage changes and market capitalization data for each listed stock.

Aptevo Therapeutics Inc. (APVO) stock plummeted 36% to $0.5920 as the company prepares for a 1-for-18 reverse stock split, effective December 29, 2025. This consolidation will reduce outstanding shares significantly, with the stock trading on a split-adjusted basis from December 30. The sharp drop and continued selling pressure reflect market anticipation and bearish sentiment surrounding the reverse split, despite the company's efforts to maintain Nasdaq listing standards and improve marketability.

Aptevo Therapeutics announced promising Phase 1b/2 RAINIER trial results for mipletamig in combination with azacitidine and venetoclax for newly diagnosed AML patients. The trial showed high remission rates and a strong safety profile, indicating mipletamig's potential as a frontline AML treatment. Despite the promising clinical data, TipRanks’ AI Analyst, Spark, rates Aptevo Therapeutics (APVO) as Underperform due to challenging financial performance and bearish momentum.

Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...